To Help Accelerate Development of Cancer Treatments with Real-World Data, COTA Welcomes Kevin Schweikert as Vice President, Life Sciences

COTA is pleased to announce Kevin Schweikert has joined the company as vice president, life sciences. With more than 20 years of experience in life sciences business development, Kevin has  partnered with the most innovative pharmaceutical companies in the business, and the vendors these companies turn to for real-world data and analytics.

Prior to COTA, Kevin worked as area vice president for Veradigm – provider of healthcare data and technology, and a business unit of Allscripts Healthcare Solutions. There, he focused on advancing the use of real-world data to support drug development across the product life cycle.  Prior to that, Kevin also supported business development in healthcare and the life sciences at: Aetion, Tempus, and OptumInsight.

Kevin’s proven track record of working collaboratively with prospects and customers to increase their utilization of real-world data to generate insights will support COTA’s mission to bring clarity to cancer care in the years to come.

Learn more about Vice President, Life Sciences, Kevin Schweikert…         

What excites you most about joining COTA?

COTA’s focus on leveraging the clinical knowledge gained by precise and thorough examination of RWD at the individual patient record level.

Having many years of experience within healthcare and pharma, what is the biggest impact you have seen from real-world data?

The speed and scale at which insights can be gained in order to bring drugs to market sooner, and at a lower cost.

How have you personally been impacted by cancer?

Thankfully, I have a close friend and a family member who were both diagnosed early, successfully treated and are now completely cancer-free.